Amin Hussein Saad, Arafa Mostafafa Ahmed, Farhat Karim Hamda, Rabah Danny Munther, Altaweel Abdulaziz Abdullah, Alhammad Abdulaziz Hamed
Department of Family and Community Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Cancer Research Chair, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Afr Health Sci. 2020 Dec;20(4):1870-1874. doi: 10.4314/ahs.v20i4.43.
Men over 50 should discuss the benefits and harms of prostate-specific antigen (PSA) testing with their doctors.
To investigate whether shared decision making (SDM) increases the uptake of prostate cancer screening practices among Saudi men.
This community-based study recruited men aged ≥ 50 years between January and April 2019. Sociodemographic characteristics, history, and current medical condition information were collected. SDM information with regards to prostate cancer screening was discussed.
In total, 2034 Saudi men, aged between 50 and 88 years, agreed to participate in the current study. Prostate examination for early detection of cancer was recommended for 35.4% (720) of subjects. Of the subjects, 23.3% (473) reported that the physicians discussed the advantages and benefits of PSA testing, whereas only 5.6% (114) stated that the physicians explained the disadvantages and drawbacks of PSA testing.
Our findings suggest that less than one fourth discussed the advantages and disadvantages of PSA testing with their physicians; of these, less than one third underwent PSA blood tests. Improvements are needed in SDM for and against PSA screening. SDM does not affect the intensity of PSA testing. Primary health care physicians should be actively involved in the SDM process.
50岁以上男性应与医生讨论前列腺特异性抗原(PSA)检测的利弊。
调查共同决策(SDM)是否能提高沙特男性对前列腺癌筛查措施的接受程度。
这项基于社区的研究在2019年1月至4月招募了年龄≥50岁的男性。收集了社会人口学特征、病史和当前医疗状况信息。讨论了有关前列腺癌筛查的共同决策信息。
共有2034名年龄在50至88岁之间的沙特男性同意参与本研究。35.4%(720名)受试者被建议进行前列腺检查以早期发现癌症。在这些受试者中,23.3%(473名)报告称医生讨论了PSA检测的优势和益处,而只有5.6%(114名)表示医生解释了PSA检测的劣势和缺点。
我们的研究结果表明,不到四分之一的人与其医生讨论了PSA检测的优缺点;其中,不到三分之一的人接受了PSA血液检测。在支持和反对PSA筛查的共同决策方面需要改进。共同决策不会影响PSA检测的强度。初级保健医生应积极参与共同决策过程。